Han Zhao1,2, Jingchao Hu2,3, Li Zhao4,5,6. 1. Multi-disciplinary Treatment Center, Beijing Stomatological Hospital, School of Stomatology, Capital Medical University, Tian Tan Xi Li Number.4, Beijing, 100050, China. 2. Department of Periodontology, Witten/Herdecke University, Alfred-Herrhausen-Str. 45, 58445, Witten, Germany. 3. Department of Periodontics, Beijing Stomatological Hospital, School of Stomatology, Capital Medical University, Tian Tan Xi Li Number 4, Beijing, 100050, China. 4. Department of Prosthodontics, Stomatological Hospital of Chongqing Medical University, Chongqing, 400015, China. lizhao2010@hospital.cqmu.edu.cn. 5. Chongqing Key Laboratory of Oral Diseases and Biomedical Sciences, Chongqing, 400015, China. lizhao2010@hospital.cqmu.edu.cn. 6. Chongqing Municipal Key Laboratory of Oral Biomedical Engineering of Higher Education, Chongqing, 400015, China. lizhao2010@hospital.cqmu.edu.cn.
Abstract
OBJECTIVES: The aim is to explore the optimal drug dose and duration of adjunctive Amoxicillin-plus-Metronidazole (AMX/MET) to full-mouth scaling and planing (FMSRP) in periodontitis. METHODS: An electronic search in four databases and manual search in four journals were conducted for randomised clinical trials comparing AMX/MET adjunct to FMSRP with FMSRP alone for at least 3 months. RESULTS: Eleven studies were eligible and included. The primary outcome was clinical attachment level (CAL) gain, the secondary outcomes were periodontal pocket depth (PPD) reduction and adverse events. Our results showed a beneficial effect of adjunctive AMX/MET with higher drug dose to FMSRP for CAL gain and PPD reduction at 3 months, and the benefit remained stable at 6 months. However, minimal difference among three-seven-and ten-day drug duration was observed. In addition, the risk difference of adverse events was minimal between two groups. CONCLUSION: FMSRP adjunct to a high drug dose of 500/500 mg of AMX/MET showed a significant and stable improvement on 6-month follow-up period. No decision for drug duration could be made due to limited evidence. CLINICAL RELEVANCE: On 6-month follow-up, higher dose of AMX/MET adjunct to FMSRP could provide a stable clinical effect. No recommendation for drug duration could be made.
OBJECTIVES: The aim is to explore the optimal drug dose and duration of adjunctive Amoxicillin-plus-Metronidazole (AMX/MET) to full-mouth scaling and planing (FMSRP) in periodontitis. METHODS: An electronic search in four databases and manual search in four journals were conducted for randomised clinical trials comparing AMX/MET adjunct to FMSRP with FMSRP alone for at least 3 months. RESULTS: Eleven studies were eligible and included. The primary outcome was clinical attachment level (CAL) gain, the secondary outcomes were periodontal pocket depth (PPD) reduction and adverse events. Our results showed a beneficial effect of adjunctive AMX/MET with higher drug dose to FMSRP for CAL gain and PPD reduction at 3 months, and the benefit remained stable at 6 months. However, minimal difference among three-seven-and ten-day drug duration was observed. In addition, the risk difference of adverse events was minimal between two groups. CONCLUSION: FMSRP adjunct to a high drug dose of 500/500 mg of AMX/MET showed a significant and stable improvement on 6-month follow-up period. No decision for drug duration could be made due to limited evidence. CLINICAL RELEVANCE: On 6-month follow-up, higher dose of AMX/MET adjunct to FMSRP could provide a stable clinical effect. No recommendation for drug duration could be made.
Authors: M Quirynen; R Vogels; M Pauwels; A D Haffajee; S S Socransky; N G Uzel; D van Steenberghe Journal: J Dent Res Date: 2005-04 Impact factor: 6.116
Authors: Bushra Bilal; Rimsha Niazi; Sohail Nadeem; Muhammad Asim Farid; Muhammad Shahid Nazir; Toheed Akhter; Mohsin Javed; Ayesha Mohyuddin; Abdul Rauf; Zulfiqar Ali; Syed Ali Raza Naqvi; Nawshad Muhammad; Eslam B Elkaeed; Hala A Ibrahium; Nasser S Awwad; Sadaf Ul Hassan Journal: Front Chem Date: 2022-04-19 Impact factor: 5.545